Business
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the issuance of a new U.S. patent entitled “Fibroblast Cell Therapy for Treatment of Osteoporosis.” The United States Patent and Trademark Office has
About this update from Fibrobiologics, Inc.
[{"type":"image","alt":"FibroBiologics, Inc.","displaySize":"","headline":null,"caption":"FibroBiologics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":77,"url":"https://media.zenfs.com/en/globenewswire.com/ea452943381e269d15ec4a2f87674425"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xw_QEbMhw7ViThavcOHCOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ea452943381e269d15ec4a2f87674425","width":300,"height":77}},"lazy":false},{"type":"text","content":"HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the issuance of a new U.S. patent entitled “Fibroblast Cell Therapy for Treatment of Osteoporosis.”","length":454,"tagName":"p"},{"type":"text","content":"The United States Patent and Trademark Office has issued U.S. Patent No. 12,544,407 B2, dated February 10, 2026, further strengthening FibroBiologics’ intellectual property portfolio in regenerative medicine and bone-related disorders.","length":235,"tagName":"p"},{"type":"text","content":"The patent covers methods of treating bone diseases or disorders, including osteoporosis, through the administration of fibroblast cells. The claims encompass systemic or local administration of fibroblasts, including modified fibroblasts, to modulate bone remodeling by inhibiting osteoclast activity and/or promoting osteoblast activity.","length":339,"tagName":"p"},{"type":"text","content":"Specifically, the issued patent includes claims directed to:","length":60,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Methods of treating osteoporosis through administration of fibroblasts expressing recombinant CXCR4 or recombinant hTERT.","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Dedifferentiated fibroblasts generated through expression of OCT4, NANOG, and/or SOX2.","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"Fibroblasts selected for specific marker profiles, including CD73, CD56, CD140, CD105, CD90, CD36, and CD146.","length":109,"tagName":"p"}]},{"val":[{"type":"t...